• 1
    Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 19721977.
  • 2
    Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004; 81: 7073.
  • 3
    Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005; 20: 367370.
  • 4
    Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67: 908910.
  • 5
    Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007; 69: 12701277.
  • 6
    Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008; 65: 379382.
  • 7
    Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 16511661.
  • 8
    Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66: 578583.
  • 9
    Bras J, Singleton A, Cookson MR, Hardy J. Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008; 275: 57675773.
  • 10
    Schlossmacher MG, Cullen V, Muthing J. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005; 352: 728731; author reply 728–731.
  • 11
    Cullen V, Lindfors M, Ng J, et al. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain 2009; 2: 5.
  • 12
    Qiao L, Hamamichi S, Caldwell KA, et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008; 1: 17.
  • 13
    Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008; 47: 96789687.
  • 14
    Heinrich M, Wickel M, Winoto-Morbach S, et al. Ceramide as an activator lipid of cathepsin D. Adv Exp Med Biol 2000; 477: 305315.
  • 15
    Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 2010; 19: 37713781.
  • 16
    Urban DJ, Zheng W, Goker-Alpan O, et al. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening. Comb Chem High Throughput Screen 2008; 11: 817824.
  • 17
    LaVoie MJ, Ostaszewski BL, Weihofen A, et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 12141221.
  • 18
    Mirzaei H, Schieler JL, Rochet JC, Regnier F. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. Anal Chem 2006; 78: 24222431.
  • 19
    Cabrera-Salazar MA, Bercury SD, Ziegler RJ, et al. Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Exp Neurol 2010; 225: 436444.
  • 20
    van Weely S, van den Berg M, Barranger JA, et al. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J Clin Invest 1993; 91: 11671175.
  • 21
    Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008; 213: 315325.
  • 22
    Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 2008; 105: 1090710912.
  • 23
    Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 2003; 163: 20932101.
  • 24
    Sun Y, Quinn B, Witte DP, Grabowski GA. Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res 2005; 46: 21022113.
  • 25
    Saftig P, Hetman M, Schmahl W, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995; 14: 35993608.
  • 26
    Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002; 160: 16551667.
  • 27
    Schlossmacher MG, Shimura H. Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. Methods Mol Biol 2005; 301: 351369.
  • 28
    Cronin KD, Ge D, Manninger P, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009; 18: 32743285.
  • 29
    Crawford GD Jr, Le WD, Smith RG, et al. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci 1992; 12: 33923398.
  • 30
    Sharon R, Goldberg MS, Bar-Josef I, et al. Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 2001; 98: 91109115.
  • 31
    Fabrega S, Durand P, Codogno P, et al. Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells. Glycobiology 2000; 10: 12171224.
  • 32
    Webb JL, Ravikumar B, Atkins J, et al. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278: 2500925013.
  • 33
    Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007; 3: 331338.
  • 34
    Lieberman RL, Wustman BA, Huertas P, et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 2007; 3: 101107.
  • 35
    Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 2973929752.
  • 36
    Sun Y, Liou B, Ran H, et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 2010; 19: 10881097.
  • 37
    Xu YH, Sun Y, Ran H, et al. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 2010 Dec 31 [Epub ahead of print]; in press. PMID: 21257328.
  • 38
    Manning-Bog AB, Schule B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009; 30: 11271132.
  • 39
    Zheng W, Padia J, Urban DJ, et al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A 2007; 104: 1319213197.
  • 40
    Tomlinson JJ, Cullen V, Schlossmacher MG. Identifying targets in alpha-synuclein metabolism to treat Parkinson's and related disorders. In: Ramirez-Alvaro M, Kelly JW, Dobson CM, eds. Protein misfolding diseases: current and emerging principles and therapies. Hoboken, NY: Wiley & Sons, 2010; 37; 817844.
  • 41
    Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19: 16331650.
  • 42
    Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007; 69: 20932104.
  • 43
    Klein C, Lohmann-Hedrich K, Rogaeva E, et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652662.